Shionogi: all 157 studies

Page 1 of 2. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy ControlsNot yet recruitingNCT07857837Phase 1
• A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD)Not yet recruitingNCT07787650Phase 1
• An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)Not yet recruitingNCT07750990Phase 2
• Study of Secutrelvir in Participants With COVID-19RecruitingNCT07746544Phase 3
• A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe DiseaseRecruitingNCT07743580Phase 3
• A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe DiseaseRecruitingNCT07214571Phase 2
• Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)RecruitingNCT07123155Phase 2
• Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult ParticipantsRecruitingNCT07093580Phase 1
• Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving OpioidsRecruitingNCT05588323Phase 1/2
• S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid TumorsRecruitingNCT05101070Phase 1/2
• Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 InfectionCompletedNCT05897541Phase 3Results posted
• Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALSCompletedNCT05568615Phase 3Results posted
• A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy ParticipantsCompletedNCT05395104Phase 1Results posted
• Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)CompletedNCT05342597Phase 1Results posted
• A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19CompletedNCT05305547Phase 3Results posted
• A Study of S-268019 for the Prevention of COVID-19CompletedNCT05212948Phase 3Results posted
• Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALSTerminatedNCT05151471Phase 3Results posted
• Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric TubeCompletedNCT04776135Phase 1Results posted
• Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT04577404Phase 3Results posted
• Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALSTerminatedNCT04569084Phase 3Results posted
• Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult SubjectsCompletedNCT04493281Phase 1Results posted
• Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)CompletedNCT04481789Phase 1Results posted
• Study of Oral Edaravone in Healthy Adult MalesCompletedNCT04481750Phase 1Results posted
• Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 DiabetesCompletedNCT04465877Phase 1Results posted
• A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel TransectionTerminatedNCT04355169Phase 2Results posted
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric ParticipantsCompletedNCT04335539Phase 2Results posted
• Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With GastrostomyCompletedNCT04254913Phase 1Results posted
• Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral SclerosisCompletedNCT04176224Phase 1Results posted
• Safety Study of Oral Edaravone Administered in Subjects With ALSCompletedNCT04165824Phase 3Results posted
• Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy AdultsCompletedNCT04147715Phase 1Results posted
• Evaluation of S-600918 in Adults With Refractory Chronic CoughCompletedNCT04110054Phase 2Results posted
• A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy SubjectsCompletedNCT04029090Phase 1Results posted
• Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial PneumoniaTerminatedNCT03862040Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT03832738Phase 2Results posted
• Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's SubjectsCompletedNCT03817684Phase 2Results posted
• PK Study in Subjects With Severe Hepatic ImpairmentCompletedNCT03664544Phase 1Results posted
• A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X SyndromeCompletedNCT03569631Phase 2Results posted
• A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive DisorderTerminatedNCT03395353Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque PsoriasisTerminatedNCT03358290Phase 2Results posted
• Dose Finding Study of MCI-186 in Acute Ischemic StrokeTerminatedNCT03346538Phase 2Results posted
• A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive DisorderCompletedNCT03315793Phase 3Results posted
• Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic ImpairmentCompletedNCT03289234Phase 1Results posted
• Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal ImpairmentCompletedNCT03289208Phase 1Results posted
• Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative PathogensCompletedNCT03032380Phase 3Results posted
• A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With InfluenzaCompletedNCT02954354Phase 3Results posted
• Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza ComplicationsCompletedNCT02949011Phase 3Results posted
• Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid ArthritisCompletedNCT02919475Phase 2Results posted
• Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative PathogensCompletedNCT02714595Phase 3Results posted
• Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to MenopauseCompletedNCT02638337Phase 3Results posted
• Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive ProceduresCompletedNCT02389621Phase 3Results posted
• A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract InfectionsCompletedNCT02321800Phase 2Results posted
• Efficacy and Safety of Naldemedine in Treating Opioid-induced ConstipationCompletedNCT01993940Phase 3Results posted
• Long Term Safety of NaldemedineCompletedNCT01965652Phase 3Results posted
• Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced ConstipationCompletedNCT01965158Phase 3Results posted
• Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a UterusCompletedNCT01586364Phase 3Results posted
• Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact UterusCompletedNCT01585558Phase 3Results posted
• Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral SclerosisCompletedNCT01492686Phase 3Results posted
• A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid TherapyCompletedNCT01443403Phase 2Results posted
• An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)TerminatedNCT01129024Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic PainCompletedNCT01122030Phase 2Results posted
• A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)TerminatedNCT01054443Phase 2Results posted
• Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic StrokeCompletedNCT00821821Phase 2Results posted
• Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual ActivityCompletedNCT00729469Phase 3Results posted
• Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT00723190Phase 3Results posted
• A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal WomenCompletedNCT00630539Phase 2Results posted
• A Clinical Study to Evaluate the Safety of OspemifeneCompletedNCT00566982Phase 3Results posted
• Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic ConditionsCompletedNCT00491894Phase 3Results posted
• Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00424463Phase 3Results posted
• Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification IIICompletedNCT00415519Phase 3Results posted
• Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00330681Phase 3Results posted
• A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal WomenCompletedNCT00276094Phase 3Results posted
• Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic StrokeCompletedNCT00200356Phase 4Results posted
• Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)CompletedNCT07247266Phase 1
• A Study of S-892216-PO in Participants With Renal Impairment and Matched ControlsCompletedNCT07217886Phase 1
• A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal ImpairmentCompletedNCT07104162Phase 1
• Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male ParticipantsCompletedNCT07083817Phase 1
• Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy ControlsCompletedNCT07018492Phase 1
• Study of BPN14770 in Participants With Severe Renal Impairment and Healthy ControlsCompletedNCT07012005Phase 1
• A Study to Assess the Effects of BPN14770 on RosuvastatinCompletedNCT07011992Phase 1
• A Study of S-892216 in Participants With COVID-19CompletedNCT06928051Phase 2
• Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep ApneaActive, not recruitingNCT06776432Phase 2
• A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female ParticipantsCompletedNCT06775730Phase 1
• A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult ParticipantsCompletedNCT06751017Phase 1
• A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric ParticipantsCompletedNCT06746051
• A Study of S-740792 in Healthy Adult Study ParticipantsCompletedNCT06724978Phase 1
• Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])Active, not recruitingNCT06717438Phase 2
• A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult ParticipantsCompletedNCT06547554Phase 1
• A Study to Investigate Different Formulations of S-337395 in Healthy Adult ParticipantsCompletedNCT06270511Phase 1
• PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal ImpairmentCompletedNCT06157242Phase 1
• Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy ParticipantsCompletedNCT06106334Phase 1
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and InfantsCompletedNCT06086626Phase 2
• P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy ParticipantsCompletedNCT06079775Phase 1
• Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection FractionCompletedNCT06017609Phase 2
• A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic StrokeCompletedNCT05953480Phase 2
• Safety and Efficacy Study of S-309309 in Obese AdultsCompletedNCT05925114Phase 2
• Use of Cefiderocol in the Management of Gram-Negative InfectionsCompletedNCT05789199
• A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control ParticipantsCompletedNCT05409911Phase 1
• An Open-Label Extension Study of BPN14770 in Subjects With Fragile X SyndromeActive, not recruitingNCT05367960Phase 3
• A Study to Assess S-217622 in Participants With Renal Impairment and Healthy ParticipantsCompletedNCT05363215Phase 1
• A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X SyndromeCompletedNCT05358886Phase 3

← Shionogi overview and focus areas